Doximity (DOCS) is back in focus after its share price reacted to shifting analyst forecasts ahead of the upcoming earnings release, with investors weighing expectations for lower EPS against modest revenue growth.

The stock has staged a short term rebound, with a 7 day share price return of 6.51% and a 30 day share price return of 15.69%. However, this sits against a year to date share price return decline of 39.87% and a 1 year total shareholder return decline of 56.14%. This suggests that recent momentum is building after a tougher period, as investors reassess growth prospects and risks ahead of earnings.

If you are looking beyond Doximity in the healthcare technology space, this is a useful moment to scan other opportunities in healthcare focused AI. Check out the 35 healthcare AI stocks

With Doximity trading below some analyst price targets and sentiment reset after weaker billings and softer expectations, is the recent rebound an early entry point, or is the stock already pricing in its future growth?

Most Popular Narrative: 31.1% Undervalued

With Doximity last closing at $26.03 against a narrative fair value of $37.77, the most followed thesis sees a sizeable gap that depends heavily on long term engagement and AI driven tools.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time. This is cited as supporting long-term revenue and margin expansion.

Want to see what kind of revenue growth path and margin profile that statement assumes? The fair value hinges on a specific mix of steady top line expansion, resilient profitability, and a richer earnings multiple tied to those outcomes.

The narrative applies an 8.25% discount rate to convert those future earnings and cash flows into today’s $37.77 fair value estimate, so understanding how realistic the embedded growth and margin path feels to you is crucial when comparing that figure with the current $26.03 share price.

Result: Fair Value of $37.77 (UNDERVALUED)

However, the thesis also leans on assumptions that could break, including slower revenue visibility and the decision to keep key AI tools free for now.

Next Steps

With sentiment clearly mixed, this is a good moment to look through the underlying data yourself and decide how compelling Doximity's strengths really are, then weigh those positives using the 4 key rewards

Looking for more investment ideas?

If Doximity has sharpened your thinking, do not stop here. Broaden your watchlist with other stocks that fit clear, data backed themes.

• Target potential mispricings by scanning companies that combine quality and compelling valuations through the 51 high quality undervalued stocks.
• Strengthen your income focus by zeroing in on reliable high yield opportunities using the 12 dividend fortresses.
• Lower your risk profile by filtering for companies with resilient fundamentals via the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.